Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 3 × Lutetium × Genitourinary × Clear all

Phase

Phase 2 3 Phase 1 3 Phase EARLY_PHASE1 1 Phase 4 1 Phase 3 1 Phase 1/2 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1 Genitourinary 1 Endocrine 1

Conditions

Prostate Cancer Metastatic 1

Interventions

Docetaxel 68 Radiotherapy 65 Prednisone 60 Leuprolide 43 Goserelin 43 Gemcitabine 42 Cisplatin 42 bicalutamide 41 enzalutamide 37 Androgen Antagonists 31 pembrolizumab 27 acetyl-2-naphthylalanyl-3-chlorophenylalanyl-1-oxohexadecyl-seryl-4-aminophenylalanyl(hydroorotyl)-4-aminophenylalanyl(carbamoyl)-leucyl-ILys-prolyl-alaninamide 27 Mitomycin 27 Carboplatin 26 Abiraterone Acetate 26 Magnetic Resonance Spectroscopy 25 Flutamide 22 apalutamide 21 Triptorelin Pamoate 21 Sunitinib 20 Nivolumab 20 Radiation 19 Doxorubicin 17 Paclitaxel 15 Gonadotropin-Releasing Hormone 15 darolutamide 14 cabozantinib 14 Zoledronic Acid 14 cabazitaxel 13 atezolizumab 13

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06320067 2025-09-26

STAMPEDE2

University College, London

Phase 3 Recruiting

Prostate Cancer Metastatic

Data powered by HemOnc (CC BY 4.0) Colophon ⚡